Loading menu...

Prostate Cancer (PCa) will affect most men if they live long enough and PCa is one of the leading causes of cancer deaths.

 
Each year over 200,000 men are newly diagnosed with PCa in North America.  CPC-100 is for asympotomatic PCa patients who fail prostate removal & hormone therapy  with no approved drug. 

Colby Pharmaceutical Company is engaged in discovery and development of novel small molecule drugs targeting prostate and other cancers. read more »

 
 

Colby drugs have activity against recurrent and metastatic prostate cancer in animal model

Colby has identified four signal transduction inhibitor drug candidates for treatment of prostate cancer, each targeting cellular  metabolic pathways.
 
With access to data from grants from NCI, DOD and other government and private instututions, Colby has demonstrated prostate cancer remission and significantly longer survival time in animal models.  read more »
 

Genomics and Proteomics Platform for small molecule drug discovery and development 

Colby's Technology Platform accesses chemistry and genomics driven drug discovery and development technology identifying multiple signaling pathways involved in therapy of prostate and other diseases. read more»
 

Disclaimer and Forward-Looking Statements

This web site contains "forward-looking statements," including statements about the Company's growth, future operating results, discovery and development of products, strategic alliances and intellectual property.Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, compensation arrangements, financing needs, plans or intentions relating to acquisitions, business trends and other information that is not historical information. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery, pre-clinical and clinical development programs; failure to obtain grants; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; difficulties or delays in obtaining regulatory approvals to market products and services resulting from the Company's development efforts; product withdrawals; competitive factors; difficulties or delays in commercialization of Company's products; and the requirement for substantial funding to conduct research and development and to expand commercialization activities.

 

Highlights


Recent Events:

2009:

11.03.09 David Zarling, PhD, MBA presents at Life Science Innovators Venture Forum
26.02.09 David Zarling, PhD, MBA presents at CHI Molecular Medicine Tri-Conference 
 

read more >>

   

Meet Colby Executives